MANAGEMENT OF PATIENTS WITH THYROIDASSOCIATED OPHTHALMOPATHY: ROLE OF SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY Tiroid İlişkili Oftalmopatili Hastaların Yönetimi: Spektral Alan Optik Koherens Tomografinin Rolü

ABSTRACT Objective: To demonstrate the changes in optic nerve head (ONH), retinal nerve fiber layer (RNFL) and macula in patients with thyroid-associated ophthalmopathy (TAO) by spectral domain optical coherence tomography (SD-OCT). Material and Methods: We included forty-one eyes of 41 patients with a diagnosis of TAO and forty-eight eyes of 48 age- and sex-matched healthy subjects (control group) from June 2016 to July 2018. The ONH parameters, RNFL and macular thicknesses in the nine macular quadrants were measured with SD-OCT. Proptosis level was determined by Hertel exophthalmometer. Clinical activity score (CAS) according to the European Group of Graves' Orbitopathy (EUGOGO) guidelines was determined in all patients. Student t-test was used to compare study and control groups. A p value less than 0.05 was considered as statistically significant. Results: Superior, inferior, and average RNFL thicknesses were significantly lower in the TAO group compared to the control group (p

___

  • 1. Şahlı E, Gündüz K. Thyroid-associated Ophthalmopathy. Turk J Ophthalmol. 2017;47(2):94-105
  • 2. Bahn RS. Thyrotropin receptor expression in orbital adipose/connective tissues from patients with thyroid-associated ophthalmopathy. Thyroid. 2002;12(3):193-5.
  • 3. F. Menconi, C. Marcocci, and M. Marino, “Diagnosis and `classification of Graves’ disease,” Autoimmunity Reviews. 2014;13(4-5), 398–402
  • 4. Kalmann R, Mourits MP. Late recurrence of unilateral graves orbitopathy on the contralateral side. Am J Ophthalmol. 2002;133(5):727-9
  • 5. Eckstein AK, Plicht M, Lax H, Neuhäuser M, Mann K, Lederbogen S, et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab. 2006;91(9):3464-70.
  • 6. Blum Meirovitch S, Leibovitch I, Kesler A, Varssano D, Rosenblatt A, Neudorfer M. Retina and Nerve Fiber Layer Thickness in Eyes with Thyroid-Associated Ophthalmopathy. Isr Med Assoc J. 2017;19(5):277-81.
  • 7. Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, et al European Group on Graves' Orbitopathy (EUGOGO). The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. Eur Thyroid J. 2016;5(1):9-26.
  • 8. Anderson RL, Tweeten JP, Patrinely JR, Garland PE, Thiese SM. Dysthyroid optic neuropathy without extraocular muscle involvement. Ophthalmic Surg. 1989;20(8):568-74.
  • 9. Mugdha K, Kaur A, Sinha N, Saxena S. Evaluation of retinal nerve fiber layer thickness profile in thyroid ophthalmopathy without optic nerve dysfunction. Int J Ophthalmol. 2016;9(11):1634-37.
  • 10. Wollstein G, Ishikawa H, Wang J, Beaton SA, Schuman JS. Comparison of three optical coherence tomography scanning areas for detection of glaucomatous damage. Am J Ophthalmol. 2005;139(1):39-43.